Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

NEXT STORY
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
PREV STORY
Worldwide Dried Blood Spot Collection Cards Industry to 2027 – Increasing Demand in Several Applications Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

- Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP ...

author_avatar
NASDAQ Market News

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology

author_avatar
NASDAQ Market News

Advanced Bactericidal and Viricidal Coatings Market Size is Projected to Grow at 11.7% CAGR by 2028 – Research Insights on Key Trends, Macro-economic Indicators, Strategic Initiatives and Future Prospect: Adroit Market Research

author_avatar
NASDAQ Market News